Chavez, MD, discusses how comprehensive genomic profiling may impact the treatment and clinical management of patients with small cell lung cancer.

Utidelone is under clinical development by BioStar Pharmaceuticals and currently in Phase I for Non-Small Cell Lung Cancer.

CDR-404 is under clinical development by CDR-Life and currently in Phase I for Squamous Non-Small Cell Lung Cancer.

Adjuvant cemiplimab prolonged DFS compared with placebo for certain patients with cutaneous squamous cell carcinoma, ...

squamous cell carcinoma and large cell carcinoma. Combining genomics data from the TRACERx non-small-cell lung cancer (NSCLC) cohort and experimental data, we report that alterations in FAT1 are ...

The FDA granted priority review to a new drug application for sunvozertinib as an oral treatment for certain patients with ...

Germo Gericke, Chief Medical Officer at Ariceum Therapeutics, said: This is an important milestone, not only for Ariceum but for the whole field of targeted radionuclide cancer treatments.

Regeneron recently presented five-years results from the phase 3 EMPOWER-Lung 1 trial of Libtayo as a first-line treatment ...

The cancer therapeutics market is set to exceed $400 billion. Read why five pharmaceutical companies offer attractive ...